Phase 1, open-label, randomized study to evaluate the effect of cytochrome p450 (CYP) 3A4 inhibition on the pharmacokinetics (PK) and safety of quizartinib (Q) and its active metabolite, AC886

Authors
Category Primary study
JournalHaematologica
Year 2017
This article has no abstract
Epistemonikos ID: 9af6b8ab079590cde451d2a5d7b5d0039df4a29b
First added on: Feb 08, 2025